Perrigo Company plc (0Y5E.L)
USD 25.57
(0.04%)
USD 25.57
(0.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.65 Billion USD | 4.58% |
| 2022 | 4.45 Billion USD | 7.56% |
| 2021 | 4.13 Billion USD | -18.26% |
| 2020 | 5.06 Billion USD | 4.67% |
| 2019 | 4.83 Billion USD | 2.23% |
| 2018 | 4.73 Billion USD | -4.34% |
| 2017 | 4.94 Billion USD | -6.33% |
| 2016 | 5.28 Billion USD | 14.7% |
| 2015 | 4.6 Billion USD | 13.37% |
| 2014 | 4.06 Billion USD | 14.72% |
| 2013 | 3.53 Billion USD | 11.55% |
| 2012 | 3.17 Billion USD | 15.18% |
| 2011 | 2.75 Billion USD | 21.43% |
| 2010 | 2.26 Billion USD | 13.06% |
| 2009 | 2 Billion USD | 10.14% |
| 2008 | 1.82 Billion USD | 25.89% |
| 2007 | 1.44 Billion USD | 5.9% |
| 2006 | 1.36 Billion USD | 33.47% |
| 2005 | 1.02 Billion USD | 14.02% |
| 2004 | 898.2 Million USD | 8.74% |
| 2003 | 825.98 Million USD | -0.04% |
| 2002 | 826.32 Million USD | 9.67% |
| 2001 | 753.48 Million USD | 2.02% |
| 2000 | 738.55 Million USD | -15.84% |
| 1999 | 877.6 Million USD | -2.77% |
| 1998 | 902.6 Million USD | 6.87% |
| 1997 | 844.6 Million USD | 8.55% |
| 1996 | 778.1 Million USD | 8.51% |
| 1995 | 717.1 Million USD | 7.14% |
| 1994 | 669.3 Million USD | 17.26% |
| 1993 | 570.8 Million USD | 39.29% |
| 1992 | 409.8 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.08 Billion USD | -6.45% |
| 2024 Q2 | 1.06 Billion USD | -1.53% |
| 2023 Q4 | 1.15 Billion USD | 2.95% |
| 2023 Q2 | 1.19 Billion USD | 0.96% |
| 2023 Q1 | 1.18 Billion USD | 2.29% |
| 2023 FY | 4.65 Billion USD | 4.58% |
| 2023 Q3 | 1.12 Billion USD | -5.81% |
| 2022 Q1 | 1.07 Billion USD | -2.75% |
| 2022 FY | 4.45 Billion USD | 7.56% |
| 2022 Q3 | 1.1 Billion USD | -1.92% |
| 2022 Q4 | 1.15 Billion USD | 5.01% |
| 2022 Q2 | 1.12 Billion USD | 4.39% |
| 2021 Q3 | 1.04 Billion USD | 6.28% |
| 2021 FY | 4.13 Billion USD | -18.26% |
| 2021 Q1 | 1.01 Billion USD | -21.68% |
| 2021 Q2 | 981.1 Million USD | -2.86% |
| 2021 Q4 | 1.1 Billion USD | 5.97% |
| 2020 Q1 | 1.34 Billion USD | 1.38% |
| 2020 Q4 | 1.28 Billion USD | 6.25% |
| 2020 Q3 | 1.21 Billion USD | -0.44% |
| 2020 FY | 5.06 Billion USD | 4.67% |
| 2020 Q2 | 1.21 Billion USD | -9.09% |
| 2019 FY | 4.83 Billion USD | 2.23% |
| 2019 Q3 | 1.19 Billion USD | 3.66% |
| 2019 Q4 | 1.32 Billion USD | 11.06% |
| 2019 Q1 | 1.17 Billion USD | -1.73% |
| 2019 Q2 | 1.14 Billion USD | -2.17% |
| 2018 Q4 | 1.19 Billion USD | 5.48% |
| 2018 FY | 4.73 Billion USD | -4.34% |
| 2018 Q2 | 1.18 Billion USD | -2.51% |
| 2018 Q1 | 1.21 Billion USD | -5.15% |
| 2018 Q3 | 1.13 Billion USD | -4.49% |
| 2017 Q1 | 1.19 Billion USD | 12.48% |
| 2017 Q2 | 1.23 Billion USD | 3.68% |
| 2017 Q3 | 1.23 Billion USD | -0.53% |
| 2017 Q4 | 1.28 Billion USD | 4.21% |
| 2017 FY | 4.94 Billion USD | -6.33% |
| 2016 Q4 | 1.06 Billion USD | -21.65% |
| 2016 FY | 5.28 Billion USD | 14.7% |
| 2016 Q2 | 1.48 Billion USD | 7.07% |
| 2016 Q1 | 1.38 Billion USD | -2.92% |
| 2016 Q3 | 1.35 Billion USD | -8.51% |
| 2015 Q1 | 1.04 Billion USD | -2.11% |
| 2015 Q4 | 1.42 Billion USD | 5.96% |
| 2015 FY | 4.6 Billion USD | 13.37% |
| 2015 Q2 | 1.53 Billion USD | 45.99% |
| 2015 Q3 | 1.34 Billion USD | -12.2% |
| 2014 Q3 | 951.5 Million USD | -16.84% |
| 2014 FY | 4.06 Billion USD | 14.72% |
| 2014 Q1 | 1 Billion USD | 2.57% |
| 2014 Q2 | 1.14 Billion USD | 13.94% |
| 2014 Q4 | 1.07 Billion USD | 12.63% |
| 2013 Q3 | 933.4 Million USD | -3.5% |
| 2013 Q4 | 979 Million USD | 4.89% |
| 2013 Q1 | 919.82 Million USD | 4.18% |
| 2013 FY | 3.53 Billion USD | 11.55% |
| 2013 Q2 | 967.2 Million USD | 5.15% |
| 2012 FY | 3.17 Billion USD | 15.18% |
| 2012 Q3 | 769.81 Million USD | -7.45% |
| 2012 Q2 | 831.76 Million USD | 6.91% |
| 2012 Q1 | 778.01 Million USD | -7.18% |
| 2012 Q4 | 882.95 Million USD | 14.7% |
| 2011 Q1 | 691.56 Million USD | -3.62% |
| 2011 FY | 2.75 Billion USD | 21.43% |
| 2011 Q4 | 838.17 Million USD | 15.56% |
| 2011 Q3 | 725.29 Million USD | 2.93% |
| 2011 Q2 | 704.62 Million USD | 1.89% |
| 2010 Q3 | 641.32 Million USD | 3.54% |
| 2010 Q4 | 717.51 Million USD | 11.88% |
| 2010 Q1 | 538.3 Million USD | -7.69% |
| 2010 Q2 | 619.39 Million USD | 15.06% |
| 2010 FY | 2.26 Billion USD | 13.06% |
| 2009 Q1 | 505.9 Million USD | -9.9% |
| 2009 Q3 | 528 Million USD | 3.89% |
| 2009 Q4 | 583.16 Million USD | 10.45% |
| 2009 FY | 2 Billion USD | 10.14% |
| 2009 Q2 | 508.2 Million USD | 0.46% |
| 2008 Q4 | 561.47 Million USD | 16.92% |
| 2008 Q1 | 503.7 Million USD | 15.67% |
| 2008 Q2 | 500.2 Million USD | -0.7% |
| 2008 Q3 | 480.23 Million USD | -3.99% |
| 2008 FY | 1.82 Billion USD | 25.89% |
| 2007 Q4 | 435.48 Million USD | 13.78% |
| 2007 FY | 1.44 Billion USD | 5.9% |
| 2007 Q1 | 362.28 Million USD | -2.25% |
| 2007 Q3 | 382.74 Million USD | 2.26% |
| 2007 Q2 | 374.29 Million USD | 3.31% |
| 2006 FY | 1.36 Billion USD | 33.47% |
| 2006 Q4 | 370.62 Million USD | 8.94% |
| 2006 Q3 | 340.21 Million USD | -4.18% |
| 2006 Q2 | 355.06 Million USD | 6.85% |
| 2006 Q1 | 332.32 Million USD | -7.61% |
| 2005 Q2 | 324.53 Million USD | 47.45% |
| 2005 FY | 1.02 Billion USD | 14.02% |
| 2005 Q4 | 359.69 Million USD | 12.5% |
| 2005 Q3 | 319.73 Million USD | -1.48% |
| 2005 Q1 | 220.09 Million USD | -12.57% |
| 2004 Q2 | 212.56 Million USD | -7.88% |
| 2004 Q1 | 230.74 Million USD | -5.86% |
| 2004 FY | 898.2 Million USD | 8.74% |
| 2004 Q4 | 251.74 Million USD | 10.55% |
| 2004 Q3 | 227.71 Million USD | 7.13% |
| 2003 Q1 | 202.61 Million USD | -10.95% |
| 2003 Q4 | 245.09 Million USD | 16.82% |
| 2003 Q2 | 182.63 Million USD | -9.86% |
| 2003 Q3 | 209.8 Million USD | 14.88% |
| 2003 FY | 825.98 Million USD | -0.04% |
| 2002 Q3 | 213.21 Million USD | 17.14% |
| 2002 Q1 | 198.49 Million USD | -13.21% |
| 2002 FY | 826.32 Million USD | 9.67% |
| 2002 Q4 | 227.52 Million USD | 6.71% |
| 2002 Q2 | 182.02 Million USD | -8.3% |
| 2001 Q4 | 228.69 Million USD | 5.33% |
| 2001 Q1 | 191.95 Million USD | 0.56% |
| 2001 FY | 753.48 Million USD | 2.02% |
| 2001 Q2 | 177.31 Million USD | -7.63% |
| 2001 Q3 | 217.11 Million USD | 22.45% |
| 2000 Q1 | 181.49 Million USD | -7.96% |
| 2000 FY | 738.55 Million USD | -15.84% |
| 2000 Q3 | 193.33 Million USD | 28.5% |
| 2000 Q2 | 150.45 Million USD | -17.1% |
| 2000 Q4 | 190.88 Million USD | -1.27% |
| 1999 Q3 | 209.4 Million USD | 11.5% |
| 1999 FY | 877.6 Million USD | -2.77% |
| 1999 Q1 | 251.4 Million USD | 11.19% |
| 1999 Q2 | 187.8 Million USD | -25.3% |
| 1999 Q4 | 197.2 Million USD | -5.83% |
| 1998 Q4 | 226.1 Million USD | 6.5% |
| 1998 FY | 902.6 Million USD | 6.87% |
| 1998 Q2 | 214.4 Million USD | -4.16% |
| 1998 Q1 | 223.7 Million USD | -7.06% |
| 1998 Q3 | 212.3 Million USD | -0.98% |
| 1997 FY | 844.6 Million USD | 8.55% |
| 1997 Q3 | 223.8 Million USD | 14.07% |
| 1997 Q2 | 196.2 Million USD | -8.57% |
| 1997 Q1 | 214.6 Million USD | -3.2% |
| 1997 Q4 | 240.7 Million USD | 7.55% |
| 1996 Q3 | 212.2 Million USD | 20.84% |
| 1996 Q2 | 175.6 Million USD | -10.55% |
| 1996 Q1 | 196.3 Million USD | -2.34% |
| 1996 FY | 778.1 Million USD | 8.51% |
| 1996 Q4 | 221.7 Million USD | 4.48% |
| 1995 FY | 717.1 Million USD | 7.14% |
| 1995 Q3 | 205.1 Million USD | 17.6% |
| 1995 Q2 | 174.4 Million USD | -5.88% |
| 1995 Q4 | 201 Million USD | -2.0% |
| 1995 Q1 | 185.3 Million USD | 6.07% |
| 1994 Q4 | 174.7 Million USD | -4.38% |
| 1994 FY | 669.3 Million USD | 17.26% |
| 1994 Q3 | 182.7 Million USD | 15.49% |
| 1994 Q1 | 163.6 Million USD | -6.19% |
| 1994 Q2 | 158.2 Million USD | -3.3% |
| 1993 FY | 570.8 Million USD | 39.29% |
| 1993 Q1 | 142.2 Million USD | 0.85% |
| 1993 Q2 | 144.7 Million USD | 1.76% |
| 1993 Q3 | 173.1 Million USD | 19.63% |
| 1993 Q4 | 174.4 Million USD | 0.75% |
| 1992 Q4 | 141 Million USD | -1.33% |
| 1992 Q1 | 120.8 Million USD | 29.89% |
| 1992 Q2 | 108.8 Million USD | -9.93% |
| 1992 Q3 | 142.9 Million USD | 31.34% |
| 1992 FY | 409.8 Million USD | 0.0% |
| 1991 Q4 | 93 Million USD | 6.77% |
| 1991 Q3 | 87.1 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -5859.321% |
| Dynavax Technologies Corporation | 232.28 Million USD | -1904.271% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -22103.357% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 96.847% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -666.327% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -54205.377% |
| Illumina, Inc. | 4.5 Billion USD | -3.366% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 89.137% |
| Nektar Therapeutics | 90.12 Million USD | -5065.886% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -391455.929% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 68.93% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -3564.557% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -92.442% |
| Waters Corporation | 2.95 Billion USD | -57.474% |
| Biogen Inc. | 9.83 Billion USD | 52.666% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -2541.745% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 202.08 Million USD | -2203.783% |
| bluebird bio, Inc. | 29.49 Million USD | -15683.3% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -14798.397% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -3901.925% |
| FibroGen, Inc. | 147.75 Million USD | -3050.956% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 31.866% |
| Homology Medicines, Inc. | -6.65 Million USD | 70098.496% |
| Geron Corporation | 237 Thousand USD | -1964288.186% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -154.642% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -1065.777% |
| Myriad Genetics, Inc. | 678.4 Million USD | -586.262% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 64.508% |
| OPKO Health, Inc. | 863.49 Million USD | -439.158% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -12734.183% |
| Zoetis Inc. | 8.54 Billion USD | 45.51% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -132917.143% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -22.894% |
| Exelixis, Inc. | 1.83 Billion USD | -154.375% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 52.827% |
| uniQure N.V. | 15.84 Million USD | -29285.849% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -1620.473% |
| Verastem, Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -491.077% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -274.444% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -146.707% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -865.141% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -461.421% |
| TG Therapeutics, Inc. | 233.66 Million USD | -1892.451% |
| Blueprint Medicines Corporation | 249.38 Million USD | -1766.87% |
| Insmed Incorporated | 305.2 Million USD | -1425.386% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -17256.746% |
| Incyte Corporation | 3.69 Billion USD | -25.975% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -343.686% |